Different effect of unfractionated heparin and enoxaparin on circulating proangiogenic factors during hemodialysis: A cross-over study

Cytokine

Volumn 40, Issue 2, 2007, Pages 98-104

  Naumnik, Beata ^a   Pawlak, Krystyna ^a   Myśliwiec, Michał ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

bFGF; Hemodialysis; Heparins; VEGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; ENOXAPARIN; HEPARIN; VASCULOTROPIN 165;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; FEMALE; HEMODIALYSIS; HUMAN; IMMUNOASSAY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CROSS-OVER STUDIES; ENDOTHELIUM, VASCULAR; ENOXAPARIN; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RENAL DIALYSIS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36549000749     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2007.08.011     Document Type: Article

References (31)

1. Gross M.L., Adamczak M., Amann K., and Ritz E. Mediators of inflammatory and ischemic renal damage: the role of neoangiogenesis. J Nephrol 18 (2005) 513-520
2. Amann K., and Ritz E. Microvascular disease-the Cinderella of uraemic heart disease. Nephrol Dial Transplant 5 (2000) 1493-1503
3. Amann K., Wiest G., Zimmer G., Gretz N., Ritz E., and Mall G. Reduced capillary density in the myocardium of uremic rats-a stereological study. Kidney Int 42 (1992) 1079-1085
4. Amman K., Breitbach M., Ritz E., and Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 9 (1998) 1018-1022
5. Dikow R., Kihm L.P., Zeier M., Kapitza J., Tirnig J., Amann K., et al. Increased infarct size in uremic rats: reduced ischemia tolerance?. J Am Soc Nephrol 15 (2004) 1530-1536
6. Pawlak K., Pawlak D., and Myśliwiec M. Possible association between circulating vascular endothelial growth factor and oxidative stress markers in hemodialysis patients. Med Sci Monit 12 (2006) 181-185
7. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6 (2000) 389-395
8. Carmeliet P. Angiogenesis in health and disease. Nat Med 9 (2003) 653-660
9. Byrne A.M., Bouchier-Hayes D.J., and Harmey J.H. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 4 (2005) 777-794
10. Ng Y.S., Krilleke D., and Shima D.T. VEGF function in vascular pathogenesis. Exp Cell Res 312 (2006) 527-537
11. 165 with soluble and cell associated flk-1 receptors. J Biol Chem 17 (1994) 12456-12461
12. Veikkola T., Karkkainen M., Claesson-Welsh L., and Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60 (2000) 203-212
13. Park J.E., Keller G.A., and Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subendothelial extracellulat matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4 (1993) 1317-1326
14. Carmeliet P. Fibroblast growth factor-1 stimulates branching and survival of myocardial arteries. A goal for therapeutic angiogenesis?. Circ Res 87 (2000) 176-178
15. Roghani M., Mansukhani A., Dell'Era P., Bellosta P., Basilico C., Rifkin D.B., et al. Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding. J Biol Chem 6 (1994) 3976-3984
16. Coltrini D., Rusnati M., Zoppetti G., Oreste P., Grazioli G., Naggi A., et al. Different effects of mucosal, bovine and chemically modified heparin on selected biological properties of basic fibroblast growth factor. Biochem J 303 (1994) 583-590
17. Coltrini D., Rusnati M., Zoppetti G., Oreste P., Isacchi A., Caccia P., et al. Biochemical bases of the interaction of human basic fibroblast growth factor with glycosaminoglycans. New insights from trypsin digestion studies. Eur J Biochem 214 (1993) 51-58
18. Tyrell D.J., Kilfeather S., and Page C.P. Therapeutic uses of heparin beyond its traditional role as anticoagulant. TIBS 16 (1995) 198-204
19. Hetzel G.R., and Sucker C. The heparins: all a nephrologist should know. Nephrol Dial Transplant 20 (2005) 2036-2042
20. Vignoli A., Marchetti M., Balducci D., Barbui T., and Falanga A. Differential effect of low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. Haematologica 91 (2006) 207-214
21. Saltissi D., Morgan C., Westhuyzen J., and Healy H. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transplant 14 (1999) 2698-26703
22. Park J.E., Keller N., and Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4 (1993) 1317-1326
23. Houck K.A., Leung D.W., Rowland A.M., Winer J., and Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267 (1992) 26031-26037
24. Lee S., Jilani S.M., Nikolova G.V., Carpizo D., and Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169 (2005) 681-691
25. Fairbrother W.J., Champe M.A., Christinger H.W., Keyt B.A., and Starovasnik M.A. Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure 6 (1998) 637-648
26. Chung N.A., Lydakis C., Belgore F., Li-Saw-Hee F.L., Blann A.D., and Lip G.Y.H. Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart 89 (2003) 1411-1415
27. Thompson R.W., Whalen G.F., Saunders K.B., Hores D., and D'Ámor P.A. Heparin mediated release of fibroblast growth factor-like activity into the circulation of rabbits. Growth factors 3 (1990) 221-229
28. Medalion B., Merin G., Aingorn H., Miao H.Q., Nagler A., Elami A., et al. Endogenous basic fibroblast growth factor displaced by heparin from the lumenal surface of human blood vessels is preferentially sequestered by injured regions of the vessel wall. Circulation 95 (1997) 1853-1862
29. Salbach P.B., Brückmann M., Turovets O., Kreuzer J., Kübler W., and Walter-Sack I. Heparin-mediated selective release of hepatocyte growth factor in humans. Br J Clin Pharmacol 50 (2000) 221-226
30. Kawamoto A., Kawata H., Akai Y., Katsuyama Y., Takase E., Sasaki Y., et al. Serum levels of VEGF and basic FGF in the subacute phase of myocardial infarction. Int J Cardiol 67 (1998) 47-54
31. Ono K., Hattori H., Takeshita S., Kurita A., and Ishihara M. Structural features in heparin that interact with VEGF165 and modulate its biological activity. Glycobiology 9 (1999) 705-711